glp-1 for obesity new orleans Louisiana spent over $1B on GLP-1s in 2023. See U.S. data Louisiana allows telehealth obesity care

If they dont, they will be without drug coverage starting January 1, 2026

Comparative glycemic control, safety and patient ratings for a new 4 mm x 32G insulin pen needle in adults with diabetes

Goldman Sachs analysts estimate the market for such drugs could grow to $100 billion by 2030

And in the current prescribing environment, that gap carries real clinical consequences

Relamorelin in gastroparesis and diabetic gastroparesis: a meta-analysis on its efficacy and safety

Compounded medications can also relieve drug shortages when brand-name medications arent available so that patients can get the treatments they need